Based on the presented findings, we may conclude that serum CXCR4 is a better candidate for a tumor marker than CXCR2 in the diagnosis of PC, while serum CXCR2 is a significant predictor of PC risk. The gene discussed is CXCR2; the disease is pachyonychia congenita.